A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

NCT04927481 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has adjusted its R\&D strategy.

Conditions

Breast Cancer

Interventions

DRUG: Mitoxantrone Hydrochloride Liposome Injection

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.